MicroPort closes a new round of strategic financing

On April 15, MicroPort Scientific Corporation (Stock code: 00853.HK) announced that MicroPort CardioFlow Medtech Corporation, a subsidiary of MicroPort, had completed a new round of financing on the basis of a pre-money valuation of 1.1 billion US dollars and raised approximately US$130 million.

On April 15, MicroPort Scientific Corporation (Stock code: 00853.HK) announced that MicroPort CardioFlow Medtech Corporation, a subsidiary of MicroPort, had completed a new round of financing on the basis of a pre-money valuation of 1.1 billion US dollars and raised approximately US$130 million.

A number of well-known investment institutions participated, and the total financing amount reached 130 million US dollars.

MicroPort CardioFlow is dedicated in providing advanced minimally invasive therapies for structural heart diseases, with best-in-class R&D, manufacturing, marketing, and technical consulting capacities.

MicroPort CardioFlow independently developed the VitaFlow Transcatheter Aortic Valve System, and it’s granted with NMPA (National Medical Products Administration) approval for commercialization.

VitaFlow® Valve System launched its official commercialization in August 2019. As of April 16, 2020, the products have entered a total of 51 hospitals with TAVI capacity, including Zhongshan Hospital Affiliated to Fudan University, Chinese Academy of Medical Sciences Fuwai Hospital, the Second Affiliated Hospital of Zhejiang University School of Medicine, and Wuhan Asia Heart Hospital.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/04/24/microport-closes-a-new-round-of-strategic-financing/.

Leave a Reply

Please Login to Comment